APOE4

Byaibio

APOE4 is the apolipoprotein E ε4 allele, a risk genotype and the strongest known genetic risk factor for late-onset alzheimers disease. It is implicated in differential regional white matter vulnerability, with a reported cingulum-specific vulnerability in female APOE4 carriers. Mechanistically, recent literature frames APOE4 as a direct target for allele-specific correction, gene silencing, and CRISPR-Cas9-based editing strategies aimed at precisely modulating APOE4-associated pathways. It is also linked to vasculature-specific mechanisms in Alzheimer’s disease, suggesting effects beyond neuronal pathology. Overall, APOE4 is being studied both as a biomarker of genetic susceptibility and as a therapeutic target for next-generation genome editing approaches.

Alzheimer’s disease

  • APOE ε4 was examined as a genotype associated with differential regional white matter vulnerability in Alzheimer’s disease, with sex-specific effects noted in brain regional vulnerability analyses. (PMID:41708549)
  • Female APOE4 carriers showed cingulum-specific vulnerability, highlighting a sex- and region-dependent pattern of risk. (PMID:41708549)
  • APOE4 was described as the strongest genetic risk factor for late-onset Alzheimer’s disease and a direct target of allele-specific correction strategies. (PMID:41812941)
  • A 2026 review in Acta neurologica Belgica discussed CRISPR-Cas9 and next-generation gene-editing strategies for therapeutic intervention of neurodegenerative pathways, including APOE4-associated risk factors. (PMID:41931258)
  • A 2026 review in Neural regeneration research linked APOE4-related genetic risk to vasculature-specific mechanisms in the Alzheimer’s disease spectrum. (PMID:41975594)

Gene editing and therapeutic development

  • Gene editing technologies were discussed as a potential way to enhance stem cell therapy for Alzheimer’s disease by targeting genetic risk factors such as APOE4. (PMID:41926312)
  • CRISPR-based correction of apolipoprotein E4 was presented alongside macromolecular delivery innovations, emphasizing delivery as a key barrier for allele-specific intervention. (PMID:41812941)
  • The literature highlighted allele-specific correction and gene silencing as complementary strategies for modulating APOE4-associated pathways. (PMID:41931258)
  • CRISPR-Cas9 and next-generation editing platforms were described as precisely targeting APOE4-related mechanisms in Alzheimer’s disease. (PMID:41931258)